BCL2 and neoplasm: The selective Bcl-2 inhibitor venetoclax has demonstrated encouraging effectiveness in laboratory and animal studies and is currently undergoing pediatric phase I clinical evaluation (NCT03236857); however, preclinical research indicates that monotherapy with venetoclax typically fails to achieve complete tumor elimination due to treatment-induced resistance mechanisms.